Setareh Seyedkazemi - 15 Sep 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Development Officer
Signature: Setareh Seyedkazemi, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol: ADVM
Transactions as of: 15 Sep 2023
Net transactions value: -$9,429
Form type: 4
Filing time: 18 Sep 2023, 18:54:13 UTC
Previous filing: 03 Mar 2023
Next filing: 12 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADVM	Common Stock	Sale	$9,228	-6,071	-11%	$1.52	47,804	15 Sep 2023	Direct	F1, F2
transaction	ADVM	Common Stock	Sale	$201	-130	-0.27%	$1.55	47,674	15 Sep 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
F2	Includes 6,000 shares purchased on May 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.

Remarks:

In Reporting Person's Form 4 filed on September 16, 2022, a portion of the footnote 1 disclosure reflected that "(a) 1/3 of the shares met a performance condition on September 14, 2022 (of which 50% of these shares vested immediately and 50% of these shares will vest in six months)." The second 50% of the shares actually vested on the one-year anniversary of September 14, 2022. All other information contained in the footnote is correct.